Skip to content

Prospective Opioid-Free AIS Fusion

Comparison of Opioid-Free Versus Traditional Opioid-Containing Postoperative Pain Management Pathways for Adolescent Idiopathic Scoliosis

Status
Enrolling by invitation
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06935331
Enrollment
58
Registered
2025-04-20
Start date
2025-10-14
Completion date
2027-12-31
Last updated
2026-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent Idiopathic Scoliosis (AIS)

Keywords

Adolescent Idiopathic Scoliosis (AIS), Opioid, Pain Management Pathway

Brief summary

The purpose of this study is to compare the efficacy of a multimodal opioid-free (OF) pain management protocol with a traditional opioid-containing (OC) protocol in pediatric patients undergoing instrumented PSF for idiopathic scoliosis.

Detailed description

Opioids are the most common controlled medication used medically and non-medically by adolescents in the United States. Opioid prescribing practices are inextricably linked with the ongoing public health crisis of opioid misuse in the peri-adolescent population. However, the immediate postoperative period following instrumented posterior spinal fusion (PSF) for idiopathic scoliosis represents a difficult challenge for patients and surgeons alike - particularly with regard to pain control. Opioid medications are commonly used to manage early postoperative pain in these patients, though are associated with potentially deleterious effects and remain at the center of a national health crisis. In particular for peri-adolescent patients, opioids are known to disrupt central nervous system maturation, which may lead to long-term behavioral dysfunction, including increased vulnerability to addiction in adulthood. On the other hand, it is well-recognized that inadequate pain control is associated with atelectasis, delayed mobilization, protracted hospitalization, and increased complication rates following posterior instrumented PSF for idiopathic scoliosis. Consequently, there is a rising, unmet need to develop postoperative recovery pathways for this population, aimed at efficient and safe pain management that minimizes or eliminates opioids while ensuring a positive postoperative experience for the patient. Previous studies in adult and pediatric patients have compared traditional opioid-based pain regimens to opioid-sparing regimens in the perioperative period, but have been limited by high rates of crossover, retrospective designs, reliance on indwelling pain catheters, reliance on opioids for early postoperative analgesia, and/or lack of patient-reported outcomes. While there are growing efforts to investigate and adopt opioid-free (OF) protocols in adult orthopaedic patients, such protocols have yet to be thoroughly evaluated in the pediatric population. A prior study approved and completed (Protocol# PED032) by Dr. Michael Paloski and team demonstrated that a comprehensive, multimodal, OF pain management pathway following instrumented PSF for idiopathic scoliosis results in equivalent length of stay and fewer opioids prescribed at discharge compared with a traditional opioid-containing (OC) pathway. To our knowledge, this was the first study to show that completely OF postoperative pain management is possible in this population. Additional studies, including the study proposed here, are necessary to evaluate patient-reported outcomes in this population when OF pain management is utilized and to delineate patient-specific and procedure-specific details that may predict success with an OF regimen.

Interventions

DRUGOpioid-Free/Opioid-Avoidant

Managed post-operatively with an opioid-free pain regimen which will include: Intrafascial injection of clonidine, epinephrine, ropivacaine, and toradol solution, diluted to 100mL and injected during closure of wound Gabapentin PO 300 mg TID x 30 days Toradol IV dosed per body weight, max 30 mg q 6 hours for 24-28 hours Ibuprofen PO dosed per body weight q 6-8 hours once toradol discontinued and discharged home with PO tabs Acetaminophen PO dosed per body weight and discharged home with PO tabs Diazepam PO dosed per body weight during stay and discharged home with PO tabs Non-medicinal therapy: Ice, Aromatherapy, Music therapy, Pet therapy, Early mobilization and PT

DRUGOpioid-Containing

Managed post-operatively with a traditional opioid containing pain regimen including: Intrafascial injection of clonidine, epinephrine, ropivacaine, and toradol solution, diluted to 100mL and injected during closure of wound Post-operative morphine IV for breakthrough pain Oral narcotic (hydrocodone/acetaminophen) Gabapentin PO 300 mg TID x 30 days Toradol IV dosed per body weight, max 30 mg q 6 hours for 24-28 hours Ibuprofen PO dosed per body weight q 6-8 hours once toradol discontinued and discharged home with PO tabs Acetaminophen PO dosed per body weight and discharged home with PO tabs Diazepam PO dosed per body weight during stay and discharged home with PO tabs Non-medicinal therapy: Ice, Early mobilization and PT

Sponsors

OrthoCarolina Research Institute, Inc.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 20 Years
Healthy volunteers
No

Inclusion criteria

* Pediatric patients (10-20 years of age at the time of surgery) * Diagnosis of idiopathic scoliosis * Undergoing primary instrumented PSF

Exclusion criteria

* Age \<10 years or \>20 years at time of surgery * Patients with non-idiopathic scoliosis etiology, ie neuromuscular or syndromic scoliosis * Patients undergoing non-fusion spinal surgeries, ie growing rods or tethering

Design outcomes

Primary

MeasureTime frameDescription
Pain rating on the 10-point numeric pain rating scale (NPRS)24 hours after surgery completionPain rating on the 10-point numeric pain rating scale (NPRS) 24 hours after surgery completion

Secondary

MeasureTime frameDescription
Morphine milliequivalents (MME)Perioperative/PeriproceduralMorphine milliequivalents (MME) while inpatient
Length of hospital stayPerioperative/PeriproceduralLength of hospital stay (in days/hours)
opioid medication prescribedPerioperative/PeriproceduralPresence of opioid medication prescribed at discharge
Clinic phone calls regarding uncontrolled painThrough study completion, an average of 1 yearClinic phone calls regarding uncontrolled pain
Delayed opioid prescriptions sentThrough study completion, an average of 1 yearDelayed opioid prescriptions sent
Opioid refills requested or sentThrough study completion, an average of 1 yearNumber of opioid refills requested or sent
Unplanned emergency department or clinic visits for painThrough study completion, an average of 1 yearInstances of unplanned emergency department or clinic visits for pain
Days missed from schoolThrough study completion, an average of 1 yearNumber of days missed from school
symptomatic pseudoarthrosisThrough study completion, an average of 1 yearIncidence of symptomatic pseudoarthrosis, confirmed either with computed tomography or during subsequent surgery
Numeric Pain Rating Scale (NPRS) - PatientThrough study completion, an average of 1 yearNumeric Pain Rating Scale (NPRS) according to the patient.
Perceived Numeric Pain Rating Scale (NPRS) - Parent/GuardianThrough study completion, an average of 1 yearPerceived Numeric Pain Rating Scale (NPRS) according to Parent/Guardian (0-10 with 10 being the worst)
Patient Acceptable Symptom State (PASS) (patient)Through study completion, an average of 1 yearPatient Acceptable Symptom State (PASS) completed by patient, a single yes or no question
Patient Acceptable Symptom State (PASS) (parent/guardian)Through study completion, an average of 1 yearPatient Acceptable Symptom State (PASS) according to the parent/guardian, a single yes or no question
Opioid medication utilizationThrough study completion, an average of 1 yearOpioid medication utilization (Yes/No) after discharge

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMichael Paloski, DO

OrthoCarolina Research Institute, Inc.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 7, 2026